Qureight’s fibrosis imaging biomarker selected by Contineum Therapeutics as a secondary endpoint in Phase 2 PROPEL-IPF clinical trial
Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, and Contineum Therapeutics, Inc. (Contineum), a